{
    "nct_id": "NCT05619692",
    "title": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2025-09-11",
    "description_brief": "The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "174 participants were randomized to receive either SAGE-718 or placebo, of which 4 participants were not treated.",
            "recruitmentDetails": "Participants were enrolled at 40 investigative sites in the United States and Puerto Rico from 29 November 2022 to 09 July 2024.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo",
                    "description": "Participants received SAGE-718-matching placebo, orally, once daily (QD), throughout the treatment period up to Day 84."
                },
                {
                    "id": "FG001",
                    "title": "SAGE-718",
                    "description": "Participants received SAGE-718, 1.2 milligrams (mg), orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "87"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "87"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "79"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "77"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "10"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Participant",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "3"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Randomized but not treated",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "1"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "3"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "Full analysis set (FAS) included all participants in the Safety Set (which included all participants who were administered at least one dose of the investigational product \\[IP\\]) who had baseline and at least 1 post-baseline efficacy evaluation.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Placebo",
                    "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84."
                },
                {
                    "id": "BG001",
                    "title": "SAGE-718",
                    "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "86"
                        },
                        {
                            "groupId": "BG001",
                            "value": "84"
                        },
                        {
                            "groupId": "BG002",
                            "value": "170"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "170"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "69.5",
                                            "spread": "6.80"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "69.6",
                                            "spread": "6.83"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "69.6",
                                            "spread": "6.80"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "170"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "51"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "52"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "103"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "32"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "67"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Ethnicity (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "170"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "title": "Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "23"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "40"
                                        }
                                    ]
                                },
                                {
                                    "title": "Not Hispanic or Latino",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "62"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "67"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "129"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "Race",
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "84"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "170"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "10"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "20"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "62"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "71"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "133"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "4"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score",
                    "description": "The WAIS-IV coding test is a valid and sensitive measure of cognitive dysfunction that correlates with real-world functional outcomes (e.g., the ability to accomplish everyday tasks) and recovery from functional disability, used to assess processing speed. The participant is required to identify the symbols matched to numbers using a key and write in the symbol beneath the associated number. The total score ranges from 0 to 135 and is based on the total number of codes correctly completed over a 120-second time limit. Higher scores indicate better processing speed.",
                    "populationDescription": "Number analyzed is the number of participants with data available for analysis.",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "score on a scale",
                    "classes": [
                        {
                            "denoms": [
                                {
                                    "units": "Participants",
                                    "counts": [
                                        {
                                            "groupId": "BG000",
                                            "value": "86"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "83"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "169"
                                        }
                                    ]
                                }
                            ],
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "43.9",
                                            "spread": "14.44"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "46.5",
                                            "spread": "16.04"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "45.2",
                                            "spread": "15.26"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline in the Wechsler Adult Intelligence Scale-IV (WAIS-IV) Coding Test Score",
                    "description": "The WAIS-IV coding test is a valid and sensitive measure of cognitive dysfunction that correlates with real-world functional outcomes (e.g., the ability to accomplish everyday tasks) and recovery from functional disability, used to assess processing speed. The participant is required to identify the symbols matched to numbers using a key and write in the symbol beneath the associated number. The total score ranges from 0 to 135 and is based on the total number of codes correctly completed over a 120-second time limit. Higher scores indicate better processing speed. Positive change from baseline indicates better processing speed. Least Squares (LS) Means were calculated using a mixed-effects model for repeated measures (MMRM) approach.",
                    "populationDescription": "FAS included all participants in the Safety Set (which included all participants who were administered at least one dose of the IP) who had baseline and at least 1 post-baseline efficacy evaluation. Overall number of participants analyzed indicates number of participants with data available for analysis at a specified timepoint.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "Baseline, Day 84",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84."
                        },
                        {
                            "id": "OG001",
                            "title": "SAGE-718",
                            "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "80"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "76"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.8",
                                            "spread": "0.77"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5.3",
                                            "spread": "0.79"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "nonInferiorityType": "SUPERIORITY",
                            "pValue": "0.1642",
                            "pValueComment": "The p-value was obtained using MMRM model which included treatment, visit, treatment-by-visit interaction as categorical covariates, and WAIS-IV at baseline as continuous covariates.",
                            "statisticalMethod": "MRMM",
                            "paramType": "Difference in LS Means",
                            "paramValue": "1.5",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.64",
                            "ciUpperLimit": "3.73",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.11",
                            "estimateComment": "Difference was calculated as SAGE-718 - placebo."
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)",
                    "description": "An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as any AE on or after the first dose of IP or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.",
                    "populationDescription": "The Safety Set included all participants who were administered at least one dose of the IP.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to Day 112",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84."
                        },
                        {
                            "id": "OG001",
                            "title": "SAGE-718",
                            "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "86"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "84"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "50"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "42"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants With at Least One TEAE by Severity",
                    "description": "A TEAE is defined as any AE on or after the first dose of IP or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. Severity was assessed as:\n\n* Mild: symptoms barely noticeable to participant or does not make participant uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for relief of symptoms\n* Moderate: symptoms of a sufficient severity to make participant uncomfortable; performance of daily activity is influenced; participant is able to continue in study; treatment for symptoms may be needed\n* Severe: symptoms cause severe discomfort; symptoms cause incapacitation or significant impact on participant's daily life; severity may cause cessation of treatment with IP; treatment for symptoms may be given and/or participant hospitalized.\n\nParticipant with multiple instances of events is counted only once using maximum intensity.",
                    "populationDescription": "The Safety Set included all participants who were administered at least one dose of the IP.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to Day 112",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84."
                        },
                        {
                            "id": "OG001",
                            "title": "SAGE-718",
                            "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "86"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "84"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Mild",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "29"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Moderate",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "20"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Severe",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Participants Who Withdrew From Study Due to TEAEs",
                    "description": "An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE is defined as any AE on or after the first dose of IP or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.",
                    "populationDescription": "The Safety Set included all participants who were administered at least one dose of the IP.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Up to Day 112",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84."
                        },
                        {
                            "id": "OG001",
                            "title": "SAGE-718",
                            "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "86"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "84"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "timeFrame": "Up to Day 112",
            "description": "The Safety Set included all participants who were administered at least one dose of the IP.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Placebo",
                    "description": "Participants received SAGE-718-matching placebo, orally, QD, throughout the treatment period up to Day 84.",
                    "deathsNumAffected": 1,
                    "deathsNumAtRisk": 86,
                    "seriousNumAffected": 5,
                    "seriousNumAtRisk": 86,
                    "otherNumAffected": 17,
                    "otherNumAtRisk": 86
                },
                {
                    "id": "EG001",
                    "title": "SAGE-718",
                    "description": "Participants received SAGE-718, 1.2 mg, orally, QD for the first 6 weeks (Days 1 to 42), followed by 0.9 mg of SAGE-718 for the remainder of the treatment period up to Day 84.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 84,
                    "seriousNumAffected": 4,
                    "seriousNumAtRisk": 84,
                    "otherNumAffected": 10,
                    "otherNumAtRisk": 84
                }
            ],
            "seriousEvents": [
                {
                    "term": "Prostate cancer recurrent",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Squamous cell carcinoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Squamous cell carcinoma of the tongue",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Femoral neck fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Hip fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Upper limb fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Atrial fibrillation",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Cellulitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Carotid artery stenosis",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Completed suicide",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 84
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 7,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Upper respiratory tract infection",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 84
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 25.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 5,
                            "numAtRisk": 86
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 84
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "The PI can either be a party and subject to the same restrictions as the institution, or if not a party, the restrictions are described on the face of the contract (i.e., PI is a contractor of the institution; PI is part of a larger group of study personnel; institution has contracted with or otherwise bound all study personnel under confidentiality obligations and requirements to vest intellectual property to the institution)."
            },
            "pointOfContact": {
                "title": "Amy Bullock",
                "organization": "Sage Therapeutics",
                "email": "amy.bullock@sagerx.com",
                "phone": "617-949-5151"
            }
        }
    },
    "target_category": "cognitive enhancer",
    "drug": [
        "SAGE-718 (dalzanemdor) \u2014 small-molecule NMDA receptor positive allosteric modulator (PAM)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The trial's stated primary purpose is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's disease, and the title specifies mild cognitive impairment or mild dementia due to AD. SAGE-718 is described in the literature and company releases as an NMDA receptor positive allosteric modulator developed to improve cognitive symptoms (i.e., modulate synaptic/NMDA function), not as an antibody/vaccine or an anti-amyloid/tau disease-modifying biologic. \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Act: Extracted details \u2014 Drug: SAGE-718 (generic/experimental name dalzanemdor); Drug type/mechanism: NMDA receptor positive allosteric modulator (small molecule) aimed at improving cognition; Trial design: randomized, double-blind, placebo-controlled for cognitive outcomes. These facts support classification as a cognitive enhancer rather than a disease-targeted biologic or small-molecule aimed at amyloid/tau pathology or an agent aimed at neuropsychiatric symptoms. \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Reflect: Classification check \u2014 SAGE-718's mechanism (NMDA PAM) and the trial objective (improving cognitive performance) match the definition of 'Cognitive enhancer' (drugs improving cognitive function without primarily targeting AD pathology like amyloid or tau). There is no indication in the description that the intervention is a biologic targeting core AD pathology or that the primary aim is to treat neuropsychiatric symptoms; therefore 'cognitive enhancer' is the appropriate category. \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Web search results / supporting sources (key items): 1) Sage Therapeutics company description and LUMINARY Phase 2 results summary describing SAGE-718 as a first-in-class NMDA receptor PAM in development to improve cognitive symptoms in AD, PD, HD. \ue200cite\ue202turn0search3\ue201 2) Peer-reviewed pharmacology article characterizing SAGE-718 (dalzanemdor) as an NMDA receptor positive allosteric modulator (mechanistic data). \ue200cite\ue202turn0search2\ue201 3) PubMed/clinical pharmacology summary describing dalzanemdor (SAGE-718) early clinical studies and its investigation as an NMDAR PAM for cognitive impairment. \ue200cite\ue202turn0search4\ue201 4) Published LUMINARY study report summarizing Phase 2 open-label evaluation of SAGE-718 in MCI/mild dementia due to AD (safety and cognitive assessments). \ue200cite\ue202turn0search5\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational drug SAGE-718 (dalzanemdor) is described in multiple sources as an N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator (PAM) developed to improve cognition in neurodegenerative disorders. NMDA is a glutamatergic neurotransmitter receptor, so the mechanism is explicitly receptor modulation rather than direct anti-amyloid/tau disease modification. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act: Extracted details \u2014 Drug: SAGE-718 (dalzanemdor); Mechanism: NMDA receptor positive allosteric modulator (small molecule) aimed at improving cognitive function; Trial context: tested in MCI/mild dementia due to AD (Phase 2 randomized or Phase 2 open-label studies reported). These facts support classification under the CADRO category for neurotransmitter receptors (agents acting on neurotransmitter receptor systems). \ue200cite\ue202turn0search3\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Mapping to CADRO \u2014 the intervention targets a classical neurotransmitter receptor (NMDAR). While NMDA modulation also affects synaptic plasticity, the most specific CADRO category is D) Neurotransmitter Receptors (receptor-targeted cognitive enhancer). There is no indication this is an anti-amyloid or anti-tau biologic or a purely non-therapeutic diagnostic, so 'D) Neurotransmitter Receptors' is the appropriate classification. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Key web sources used (selected): 1) Sage Therapeutics company statement describing SAGE-718 (dalzanemdor) as an investigational NMDA receptor PAM. \ue200cite\ue202turn0search0\ue201 2) Sage press release and LUMINARY Phase 2 summary reporting cognitive outcome signals in MCI/mild dementia due to AD. \ue200cite\ue202turn0search1\ue202turn0search2\ue201 3) PubMed/clinical pharmacology article reporting dalzanemdor as an NMDAR PAM and early human safety/pharmacology data. \ue200cite\ue202turn0search3\ue201 4) Sage press release reporting LIGHTWAVE Phase 2 topline randomized, double-blind results in MCI/mild dementia due to AD. \ue200cite\ue202turn0search5\ue201"
    ]
}